Tango Therapeutics Past Earnings Performance
Past criteria checks 0/6
Tango Therapeutics's earnings have been declining at an average annual rate of -26.5%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 17.4% per year.
Key information
-26.5%
Earnings growth rate
5.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 17.4% |
| Return on equity | -53.8% |
| Net Margin | -284.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Tango Therapeutics: Chance For A Short Squeeze
Jan 23Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth?
Dec 05
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Oct 31Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data
Sep 10What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You
Sep 01Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%
Jun 29Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why
May 30Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%
Mar 19Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans
Mar 06Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk
Jan 08Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)
Aug 12Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?
May 10Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer
Oct 20Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth
Oct 05Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 13Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M
Aug 10We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn
May 28We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow
Jan 06Revenue & Expenses Breakdown
How Tango Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 43 | -123 | 42 | 0 |
| 30 Jun 24 | 43 | -116 | 40 | 0 |
| 31 Mar 24 | 37 | -112 | 38 | 0 |
| 31 Dec 23 | 37 | -102 | 36 | 0 |
| 30 Sep 23 | 38 | -100 | 34 | 0 |
| 30 Jun 23 | 34 | -107 | 33 | 0 |
| 31 Mar 23 | 25 | -111 | 31 | 0 |
| 31 Dec 22 | 25 | -108 | 30 | 0 |
| 30 Sep 22 | 24 | -101 | 28 | 0 |
| 30 Jun 22 | 24 | -92 | 25 | 0 |
| 31 Mar 22 | 36 | -71 | 21 | 0 |
| 31 Dec 21 | 37 | -58 | 18 | 0 |
| 30 Sep 21 | 40 | -45 | 15 | 0 |
| 30 Jun 21 | 22 | -52 | 13 | 0 |
| 31 Mar 21 | 9 | -56 | 11 | 0 |
| 31 Dec 20 | 8 | -52 | 10 | 0 |
| 31 Dec 19 | 25 | -14 | 8 | 0 |
Quality Earnings: TNGX is currently unprofitable.
Growing Profit Margin: TNGX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TNGX is unprofitable, and losses have increased over the past 5 years at a rate of 26.5% per year.
Accelerating Growth: Unable to compare TNGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TNGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (23.5%).
Return on Equity
High ROE: TNGX has a negative Return on Equity (-53.84%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 01:30 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tango Therapeutics, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Yuan Zhi | B. Riley Securities, Inc. |
| Eric Schmidt | Cantor Fitzgerald & Co. |